RxDoctor Payments Data

Vilma Drelichman, MD

Infectious Disease · Southfield, MINPI 1013957893

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,583 of the $1,811 with a category attached, or 87.4%. It is spread thinly across 16 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,553 and has fallen 99.7% since, to $5 in 2025.

$1,811in general payments, 2019–2025

Across 49 payments — averaging $36.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$421
  • Janssen Products, LP$268
  • Merck$185
  • Viiv Healthcare Company$156
  • Astellas Pharma US Inc$143
  • Osiris Therapeutics Inc.$130
  • plus $508 from 10 others
$347,069in research payments, 2019–2025

Across 172 payments — averaging $2017.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$138K
  • Viiv Healthcare Company$132K
  • GSK$51K
  • Emergent Biosolutions Inc.$16K
  • Amgen$7K
  • Pfizer$3K
  • plus $30 from 1 others

What the payments were for

  • Food & beverage$1,58387%
  • Education$22813%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,811 in reported general payments places this provider in the 85th percentile of 257 infectious disease providers in Michigan.

See all infectious disease providers in Michigan

Medicare billing

Part B allowed, 2024
$10,134
Medicare patients
41
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Typhim ViTyphoid Vi Polysacch Vaccine100$12,371
AbrysvoRsv Vacc, Pref A And Pref B/Pf25$7,986
HavrixHepatitis A Virus Vaccine/Pf74$7,960
IxiaroJapanese Encephalitis Vacc/Pf24$7,620
ShingrixVaricella-Zoster Ge/As01b/Pf33$7,266
Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl71$7,045
MenquadfiMening Vac A,c,y,w135,c-Tet/Pf31$5,762
Boostrix TdapDiphth,pertuss(Acell),tet Vac60$4,343
TwinrixHepatitis A And B Vaccine/Pf24$3,493
Yf-VaxYellow Fever Vaccine Live/Pf14$3,080
IpolPoliomyelitis Vaccine, Killed31$2,069
Doxycycline Hyclate21$585
Azithromycin92$347

Paid to pharmacies, not to this prescriber.

Other infectious disease in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →